PHAT Stock Analysis: Buy, Sell, or Hold?
PHAT - Phathom Pharmaceuticals, Inc. Common Stock
$10.86
0.17 (1.59%)
▲
5d:
+1.4%
30d:
-6.22%
90d:
+2.74%
BUY
HIGH Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 06, 2026
Smart Money Accumulation
None View Scanner →
Strength: 6.5/10
Get Alerted When PHAT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
🚀 STRONG BUY: PHAT shows excellent value with unusually cheap options (IV 26th percentile) and market pricing in only 0.2% annual growth despite strong fundamentals. High conviction opportunity.
🚀 STRONG BUY: PHAT shows excellent value with unusually cheap options (IV 26th percentile) and market pricing in only 0.2% annual growth despite strong fundamentals. High conviction opportunity.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$15.12
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$9.39
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 7.5x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PHAT is currently trading at $10.86, which is considered fair relative to its 30-day fair value range of $9.85 to $11.20. The stock's valuation (Forward PE: 7.5) is in line with its historical norms (7.5). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, PHAT is in a uptrend. Immediate support is located at $9.74, while resistance sits at $11.40.
Market Sentiment: PHAT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.70 (+118.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PHAT is in a uptrend. Immediate support is located at $9.74, while resistance sits at $11.40.
Market Sentiment: PHAT has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (26th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $23.70 (+118.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$9.85 -
$11.20
Company Quality Score
54/100
(HOLD)
Options IV Signal
26th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
87.3%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 26th percentile)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 118.2% below Wall St target ($23.70)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$9.85 -
$11.20
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$2.19
(20.2%)
Support & Resistance Levels
Support Level
$9.74
Resistance Level
$11.40
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
7.55
Wall Street Target
$23.70
(+118.2%)
Revenue Growth (YoY)
104.4%
Profit Margin
-76.8%
Valuation Premium vs History
+0.2% premium
PE vs Historical
7.6 vs 7.5
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$10.88
(+0%)
2-Year Target
$10.90
(+0%)
3-Year Target
$10.93
(+1%)
3-Yr Target (if PE normalizes)
(PE: 8→8)
PE COMPRESSION
$10.86
(0%)
Earnings growth offset by PE compression
Share & Embed Analysis
Last updated: June 24, 2026 1:42 AM ET
Data refreshes hourly during market hours. Next update: 2:42 AM
Data refreshes hourly during market hours. Next update: 2:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PHAT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 65 BUY |
Advanced PHAT Option Strategies
Professional options setups generated by AI based on today's PHAT price and gamma walls.
